In this episode of Signals, Nick Mazing welcomes Sara Stahl, Director of Research, Healthcare, at AlphaSense Expert Insights. They explore the new generation of weight loss drugs, a hot topic that's making waves everywhere.

The conversation focuses on the efficacy of these drugs and the massive market potential they hold. Sara highlights the rising obesity epidemic and the potential these drugs have in combating it. She discusses the mechanism of action of the GLP-1 agonists, as well as the pipeline for several companies. Sara also covers the negative side effects of these drugs, the strong demand by consumers, as well as the effects on obesity-related comorbidities.

The discussion also touches on the potential impacts of these drugs on related industries. From bariatric surgery to diabetes devices, the ripple effects are far-reaching. The episode wraps up with a look at the challenges and opportunities these drugs present for insurance coverage.

---
AlphaSense is a market intelligence and search platform used by the world’s leading companies and financial institutions.

→ Learn more about AlphaSense: https://www.alpha-sense.com

→ Engage with AlphaSense:
Twitter:   / alphasenseinc  
LinkedIn:   / alphasense  
Facebook:   / alphasenseinc  
Instagram:   / alphasenseinc  
Podcast: https://open.spotify.com/show/2Fpmsp1...
Blog: https://www.alpha-sense.com/blog